Hib vaccine conjugate - Zydus Lifesciences
Alternative Names: Hib-tetanus toxoid conjugate vaccine - Zydus LifesciencesLatest Information Update: 21 Mar 2022
Price :
$50 *
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Conjugate vaccines; Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilus infections
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Haemophilus-infections(Prevention) in India (IM)
- 22 Mar 2014 Cadila Healthcare completes phase I trials in Haemophilus infections (Prevention) in India (IM) ( CTRI2014-01-004340)